The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity
Open accessAbstract
Cytotoxic T lymphocyte antigen-4 (CTLA-4) is an essential negative regulator of T cell responses. Germline Ctla4 deficiency is lethal, making investigation of the function of CTLA-4 on mature T cells challenging. To elucidate the function of CTLA-4 on mature T cells, we have conditionally ablated Ctla4 in adult mice. We show that, in contrast to germline knockout mice, deletion of Ctla4 during adulthood does not precipitate systemic autoimmunity, but surprisingly confers protection from experimental autoimmune encephalomyelitis (EAE) and does not lead to increased resistance to MC38 tumors. Deletion of Ctla4 during adulthood was accompanied by activation and expansion of both conventional CD4+Foxp3− (T conv) and regulatory Foxp3+ (T reg cells) T cell subsets; however, deletion of CTLA-4 on T reg cells was necessary and sufficient for protection from EAE. CTLA-4 deleted T reg cells remained functionally suppressive. Deletion of Ctla4 on T reg cells alone or on all adult T cells led to major changes in the Ctla4 sufficient T conv cell compartment, including up-regulation of immunoinhibitory molecules IL-10, LAG-3 and PD-1, thereby providing a compensatory immunosuppressive mechanism. Collectively, our findings point to a profound role for CTLA-4 on T reg cells in limiting their peripheral expansion and activation, thereby regulating the phenotype and function of T conv cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992 · cited 1×
“…al., 1997; Schmidt et al., 2009), whereas others have shown that CTLA-4 plays a role in negative selection (Wagner et al., 1996; Cilio et al., 1998; Buhlmann et al., 2003; Takahashi et al., 2005), modulating the TCR repertoire and inhibiting natural T reg cell generation (Verhagen et al., 2009,…”
BackgroundSelf-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
CTLA-4 Control over Foxp3 + Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Self-citationLymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766 · cited 4×
“DISCUSSION The dramatic, lethal phenotype of the germline Ctla4 knockout mouse demonstrates the potency of this molecule as an inhibitory receptor (Tivol et al., 1995; Waterhouse et al., 1995).”
BackgroundInfluentialTakahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233 · cited 2×
“Whereas CD28 is constitutively expressed on most T cells, CTLA-4 is constitutively expressed on CD4+Foxp3+ regulatory T (T reg) cells (Metzler et al., 1999; Read et al., 2000; Takahashi et al., 2000), and appears on CD4+Foxp3 conventional T (T conv) cells after activation (Freeman et al.”
BackgroundAssociation of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease
Ueda, H., Howson, J. M. M., Esposito, L., Heward, J., Snook, Chamberlain, G., Rainbow, D. B., Hunter, K. M. D., Smith, A. N., Di Genova, G., et al. (2003) · Nature · doi:10.1038/nature01621 · Cited by 2,175
Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4
Qureshi, O. S., Zheng, Y., Nakamura, K., Attridge, K., Manzotti, C., Schmidt, E. M., Baker, J., Jeffery, L. E., Kaur, S., Briggs, Z., et al. (2011) · Science · doi:10.1126/science.1202947 · Cited by 1,860 · cited 1×
“CTLA-4 has been suggested to down-regulate B7-1 or B7-2 on APCs, either by indirect suppression of the APC, signaling through B7, or removal of B7 from the cell surface by trans-endocytosis (Fallarino et al., 2003; Onishi et al., 2008; Wing et al., 2008; Qureshi et al., 2011).”
BackgroundCTLA-4 is a second receptor for the B cell activation antigen B7.
Linsley, P. S., Brady, W., Urnes, M., Grosmaire, L. S., Damle, N. K., & Ledbetter, J. A. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.3.561 · Cited by 1,685 · cited 5×
“Importantly, we did not find increased B7 levels on the CD45 hi MHC class II + APCs in the CNS of mice immunized for EAE (Fig.”
BackgroundInfluentialSimpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472
Cited by
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
CTLA-4: a moving target in immunotherapy
Rowshanravan, B., Halliday, N., & Sansom, D. M. (2018) · Blood · doi:10.1182/blood-2017-06-741033 · Cited by 1,233
Regulatory T Cells and Human Disease
Sakaguchi, S., Mikami, N., Wing, J. B., Tanaka, A., Ichiyama, K., & Ohkura, N. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042718-041717 · Cited by 1,120
CD28 Costimulation: From Mechanism to Therapy
Esensten, J. H., Helou, Y. A., Chopra, G., Weiss, A., & Bluestone, J. A. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.020 · Cited by 937
Human FOXP3+ Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer
Wing, J. B., Tanaka, A., & Sakaguchi, S. (2019) · Immunity · doi:10.1016/j.immuni.2019.01.020 · Cited by 726
Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family
Schildberg, F. A., Klein, S. R., Freeman, G. J., & Sharpe, A. H. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.002 · Cited by 542
Self-citationEndocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints
Chang, L.-S., Barroso-Sousa, R., Tolaney, S. M., Hodi, F. S., Kaiser, U. B., & Min, L. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00006 · Cited by 532
Principles of regulatory T cell function
Dikiy, S., & Rudensky, A. Y. (2023) · Immunity · doi:10.1016/j.immuni.2023.01.004 · Cited by 445
Self-citationThe immunology of renal cell carcinoma
Díaz-Montero, C. M., Rini, B. I., & Finke, J. H. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-0316-3 · Cited by 442
Sage, P. T., & Sharpe, A. H. (2016) · Immunological Reviews · doi:10.1111/imr.12411 · Cited by 330
Self-citationCTLA-4 in Regulatory T Cells for Cancer Immunotherapy
Sobhani, N., Tardiel-Cyril, D. R., Davtyan, A., Generali, D., Roudi, R., & Li, Y. (2021) · Cancers · doi:10.3390/cancers13061440 · Cited by 303
Regulatory T cells in the treatment of disease
Sharabi, A., Tsokos, M. G., Ding, Y., Malek, T. R., Klatzmann, D., & Tsokos, G. C. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.148 · Cited by 297
Co-stimulatory and Co-inhibitory Pathways in Autoimmunity
Zhang, Q., & Vignali, D. A. A. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.017 · Cited by 296
Regulatory T Cells: Differentiation and Function
Plitas, G., & Rudensky, A. Y. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0193 · Cited by 282
Self-citationAdverse Events Following Cancer Immunotherapy: Obstacles and Opportunities
Pauken, K. E., Dougan, M., Rose, N. R., Lichtman, A. H., & Sharpe, A. H. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.04.002 · Cited by 280
Self-citationTargeting regulatory T cells in tumors
Liu, C., Workman, C. J., & Vignali, D. A. A. (2016) · The FEBS Journal · doi:10.1111/febs.13656 · Cited by 228
Plitas, G., & Rudensky, A. Y. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033428 · Cited by 148
Self-citationWei, S. C., Sharma, R., Anang, N.-A. A. S., Levine, J. H., Zhao, Y., Mancuso, J. J., Setty, M., Sharma, P., Wang, J., Pe’er, D., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.004 · Cited by 97
Halliday, N., Williams, C., Kennedy, A., Waters, E., Pesenacker, A. M., Soskic, B., Hinze, C., Hou, T. Z., Rowshanravan, B., Janman, D., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.600000 · Cited by 95
Inhibiting the coregulator CoREST impairs Foxp3+ Treg function and promotes antitumor immunity
Xiong, Y., Wang, L., Di Giorgio, E., Akimova, T., Beier, U. H., Han, R., Trevisanut, M., Kalin, J. H., Cole, P. A., & Hancock, W. W. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131375 · Cited by 72
Inhibitory receptor agonists: the future of autoimmune disease therapeutics?
Grebinoski, S., & Vignali, D. A. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.06.001 · Cited by 58
Gene therapy with regulatory T cells: A beneficial alliance
Biswas, M., Kumar, S. R. P., Terhorst, C., & Herzog, R. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00554 · Cited by 41
Metadata
- Authors
- Paterson, A. M., Lovitch, S. B., Sage, P. T., Juneja, V. R., Lee, Y., Trombley, J. D., Arancibia-Cárcamo, C. V., Sobel, R. A., Rudensky, A. Y., Kuchroo, V. K., Freeman, G. J., & Sharpe, A. H.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2015-09-14
- Volume
- 212
- Issue
- 10
- Pages
- 1603-1621
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W1914215890
- Cited by
- 212
- References
- 20
- FWCI
- 7.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.